Heat Biologics’ (HTBX) forecast will put a smile on any investors face
Heat Biologics (HTBX) currently trades at $0.59 and has fallen by 2.15% today. HTBX went down $0.013 from the previous closing price of $0.60. The high forecast for Heat Biologics is $5.00 and the low is $2.00. The company’s market cap is $46.85 million with a 52 week high of $1.27 and a 52 week low of $0.20. HTBX has changed in price by -0.52 per share in the last 12 months.
Heat Biologics has a weak EPS of -0.6. This means the company lost $-0.6 per share after paying dividends, this can indicate that the stock is a risky investment. EPS is calculated as a company’s profit divided by the outstanding shares of its common stock. The resulting number serves as an indicator of a company’s profitability. It is common for a company to report EPS that is adjusted for extraordinary items and potential share dilution. Based on this information, investorsQ rates this stock 4 out of 10. We give it this rating based on current information written in this article.
About Heat Biologics:
Heat Biologics is a biopharmaceutical company headquartered in Morrisville, NC and has operations in San Antonio, TX. The company has a proprietary gp96 platform to activate immune responses against pathogenic or cancer antigens.